国产吉西他滨与奈达铂治疗晚期非小细胞肺癌近期疗效观察  

The Observation of Short Term Efficacy in Combined Therapy with Gemcitabine and Nedaplatin in Treatment of Advanced Non-small Cell Lung Cancer

作　　者：杨洁[1] 卢文娜[1] 

机构地区：[1]贵州省人民医院肿瘤科,贵阳市550001

出　　处：《中国肿瘤临床》2006年第18期1044-1046,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察国产吉西他滨(gemcitabineGEM)与奈达铂(nedaplatinNDP)联合化疗治疗晚期非小细胞肺癌(non-smaIIceIIIungcancerNSCLC)的临床疗效及不良反应。方法:32例均为不能手术的Ⅲ～Ⅳ期非小细胞肺癌患者。吉西他滨1000mg/m2静脉滴注,第1、8或15天,奈达铂80mg/m2第1天。每21天或28天为1个周期,治疗3～4周期。结果:全组无完全缓解的患者,总有效率为46.8%(14/32)。中位生存期为325天,1年生存率为32.1%。主要不良反应为骨髓抑制及恶心、呕吐,但无严重的Ⅳ度损害;无1例因毒性反应而延期化疗。结论:吉西他滨加奈达铂联合化疗治疗晚期非小细胞肺癌有较好的疗效,且耐受较好。Objective： To observe clinical effect and adverse effect of the combined therapy of gemcitabine with nedaplatin for advanced NSCLC. Methods： A total of 32 patients were pathologically confirmed as stage m or IV NSCLC missing opportunity of surgical operation. Gemcitabine was given on day 1, 8 or 15 at a dose of 1000mg/m^2 and nedaplatin on days 1 at a dose of 80mg/m^2. The chemotherapy was repeated every 21 or 28 days up to 3-4 cycles. Results： No complete response occurred in the patients and the overall response rate was 46.8%. The median survival time was 325 days and the 1-year survival rate was 32.1%. The main adverse effects were myelosuppression, nausea and vomiting. However, there was no severe grade-Ⅳ damage. No treatment with chemotherapy was delayed due to adverse effect. Conclusion： The combined therapy with gemcitabine and nedaplation is effective and well tolerated in treatment of the advanced NSCLC.

关 键 词：吉西他滨 奈达铂 晚期 非小细胞肺癌 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]